AustralieFrV1, PascalFrancis, Corpus, bibRecord, 002E47

Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes

Identifieur interne : 002E47 ( PascalFrancis/Corpus ); précédent : 002E46; suivant : 002E48

Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes

Auteurs : Bastiaan E. De Galan ; Vlado Perkovic ; Toshiharu Ninomiya ; Avinesh Pillai ; Anushka Patel ; Alan Cass ; Bruce Neal ; Neil Poulter ; Stephen Harrap ; Carl-Erik Mogensen ; Mark Cooper ; Michel Marre ; Bryan Williams ; Pavel Hamet ; Giuseppe Mancia ; Mark Woodward ; Paul Glasziou ; Diederick E. Grobbee ; Stephen Macmahon ; John Chalmers

Source :

Journal of the American Society of Nephrology [ 1046-6673 ] ; 2009.

RBID : Pascal:09-0193729

Descripteurs français

Pascal (Inist)
- Diabète de type 2, Pression sanguine, Pression artérielle, Rein, Néphrologie, Urologie.

English descriptors

KwdEn :
- Arterial pressure, Blood pressure, Kidney, Nephrology, Type 2 diabetes, Urology.

Abstract

BP is an important determinant of kidney disease among patients with diabetes. The recommended thresholds to initiate treatment to lower BP are 130/80 and 125/75 mmHg for people with diabetes and nephropathy, respectively. We sought to determine the effects of lowering BP below these currently recommended thresholds on renal outcomes among 11,140 patients who had type 2 diabetes and participated in the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) study. Patients were randomly assigned to fixed combination perindopril-indapamide or placebo, regardless of their BP at entry. During a mean follow-up of 4.3 yr, active treatment reduced the risk for renal events by 21% (P < 0.0001), which was driven by reduced risks for developing microalbuminuria and macroalbuminuria (both P < 0.003). Effects of active treatment were consistent across subgroups defined by baseline systolic or diastolic BP. Lower systolic BP levels during follow-up, even to <110 mmHg, was associated with progressively lower rates of renal events. In conclusion, BP-lowering treatment with perindopril-indapamide administered routinely to individuals with type 2 diabetes provides important renoprotection, even among those with initial BP <120/70 mmHg. We could not identify a BP threshold below which renal benefit is lost.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 1046-6673`
A02	`01`			`@0 JASNEU`
A03		`1`		`@0 J. Am. Soc. Nephrol.`
A05				`@2 20`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes`
A11	`01`	`1`		`@1 DE GALAN (Bastiaan E.)`
A11	`02`	`1`		`@1 PERKOVIC (Vlado)`
A11	`03`	`1`		`@1 NINOMIYA (Toshiharu)`
A11	`04`	`1`		`@1 PILLAI (Avinesh)`
A11	`05`	`1`		`@1 PATEL (Anushka)`
A11	`06`	`1`		`@1 CASS (Alan)`
A11	`07`	`1`		`@1 NEAL (Bruce)`
A11	`08`	`1`		`@1 POULTER (Neil)`
A11	`09`	`1`		`@1 HARRAP (Stephen)`
A11	`10`	`1`		`@1 MOGENSEN (Carl-Erik)`
A11	`11`	`1`		`@1 COOPER (Mark)`
A11	`12`	`1`		`@1 MARRE (Michel)`
A11	`13`	`1`		`@1 WILLIAMS (Bryan)`
A11	`14`	`1`		`@1 HAMET (Pavel)`
A11	`15`	`1`		`@1 MANCIA (Giuseppe)`
A11	`16`	`1`		`@1 WOODWARD (Mark)`
A11	`17`	`1`		`@1 GLASZIOU (Paul)`
A11	`18`	`1`		`@1 GROBBEE (Diederick E.)`
A11	`19`	`1`		`@1 MACMAHON (Stephen)`
A11	`20`	`1`		`@1 CHALMERS (John)`
A14	`01`			`@1 George Institute For International Health, University of Sydney @2 Sydney @3 AUS @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 16 aut. @Z 19 aut. @Z 20 aut.`
A14	`02`			`@1 Department of General Internal Medicine, Radboud University Nijmegen Medical Centre @2 Nijmegen @3 NLD @Z 1 aut.`
A14	`03`			`@1 International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London @2 London @3 GBR @Z 8 aut.`
A14	`04`			`@1 Department of Physiology, University of Melbourne @2 Melbourne @3 AUS @Z 9 aut.`
A14	`05`			`@1 Medical Department M, Aarhus University Hospital, Aarhus Sygehus @2 Aarhus @3 DNK @Z 10 aut.`
A14	`06`			`@1 Danielle Alberti Memorial Centre for Diabetes Complications, Baker Heart Research Institute @2 Melbourne @3 AUS @Z 11 aut.`
A14	`07`			`@1 Service d'Endocrinologie Diabétologie Nutrition, Groupe Hospitalier Bichat-Claude Bernard @2 Paris @3 FRA @Z 12 aut.`
A14	`08`			`@1 Department of Cardiovascular Sciences, University of Leicester School of Medicine @2 Leicester @3 GBR @Z 13 aut.`
A14	`09`			`@1 Research Centre, Centre hospitalier de l'Université de Montréal (CHUM) @2 Montreal, Québec @3 CAN @Z 14 aut.`
A14	`10`			`@1 Department of Clinical Medicine and Prevention, University of Milano-Bicocca @2 Milan @3 ITA @Z 15 aut.`
A14	`11`			`@1 Centre for Evidence-Based Practice, Institute of Health Sciences, Oxford University @2 Oxford @3 GBR @Z 17 aut.`
A14	`12`			`@1 Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht @2 Utrecht @3 NLD @Z 18 aut.`
A17	`01`	`1`		`@1 ADVANCE Collaborative Group @3 INC`
A20				`@1 883-892`
A21				`@1 2009`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 26049 @5 354000185969410250`
A44				`@0 0000 @1 © 2009 INIST-CNRS. All rights reserved.`
A45				`@0 41 ref.`
A47	`01`	`1`		`@0 09-0193729`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of the American Society of Nephrology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 BP is an important determinant of kidney disease among patients with diabetes. The recommended thresholds to initiate treatment to lower BP are 130/80 and 125/75 mmHg for people with diabetes and nephropathy, respectively. We sought to determine the effects of lowering BP below these currently recommended thresholds on renal outcomes among 11,140 patients who had type 2 diabetes and participated in the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) study. Patients were randomly assigned to fixed combination perindopril-indapamide or placebo, regardless of their BP at entry. During a mean follow-up of 4.3 yr, active treatment reduced the risk for renal events by 21% (P < 0.0001), which was driven by reduced risks for developing microalbuminuria and macroalbuminuria (both P < 0.003). Effects of active treatment were consistent across subgroups defined by baseline systolic or diastolic BP. Lower systolic BP levels during follow-up, even to <110 mmHg, was associated with progressively lower rates of renal events. In conclusion, BP-lowering treatment with perindopril-indapamide administered routinely to individuals with type 2 diabetes provides important renoprotection, even among those with initial BP <120/70 mmHg. We could not identify a BP threshold below which renal benefit is lost.
C02	`01`	`X`		`@0 002B14`
C02	`02`	`X`		`@0 002B21E01A`
C03	`01`	`X`	`FRE`	`@0 Diabète de type 2 @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Type 2 diabetes @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Diabetes de tipo 2 @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pression sanguine @5 02`
C03	`02`	`X`	`ENG`	`@0 Blood pressure @5 02`
C03	`02`	`X`	`SPA`	`@0 Presión sanguínea @5 02`
C03	`03`	`X`	`FRE`	`@0 Pression artérielle @5 03`
C03	`03`	`X`	`ENG`	`@0 Arterial pressure @5 03`
C03	`03`	`X`	`SPA`	`@0 Presión arterial @5 03`
C03	`04`	`X`	`FRE`	`@0 Rein @5 05`
C03	`04`	`X`	`ENG`	`@0 Kidney @5 05`
C03	`04`	`X`	`SPA`	`@0 Riñón @5 05`
C03	`05`	`X`	`FRE`	`@0 Néphrologie @5 06`
C03	`05`	`X`	`ENG`	`@0 Nephrology @5 06`
C03	`05`	`X`	`SPA`	`@0 Nefrología @5 06`
C03	`06`	`X`	`FRE`	`@0 Urologie @5 08`
C03	`06`	`X`	`ENG`	`@0 Urology @5 08`
C03	`06`	`X`	`SPA`	`@0 Urología @5 08`
C07	`01`	`X`	`FRE`	`@0 Hémodynamique @5 37`
C07	`01`	`X`	`ENG`	`@0 Hemodynamics @5 37`
C07	`01`	`X`	`SPA`	`@0 Hemodinámica @5 37`
C07	`02`	`X`	`FRE`	`@0 Appareil urinaire @5 38`
C07	`02`	`X`	`ENG`	`@0 Urinary system @5 38`
C07	`02`	`X`	`SPA`	`@0 Aparato urinario @5 38`
C07	`03`	`X`	`FRE`	`@0 Endocrinopathie @5 39`
C07	`03`	`X`	`ENG`	`@0 Endocrinopathy @5 39`
C07	`03`	`X`	`SPA`	`@0 Endocrinopatía @5 39`
C07	`04`	`X`	`FRE`	`@0 Maladie métabolique @5 40`
C07	`04`	`X`	`ENG`	`@0 Metabolic diseases @5 40`
C07	`04`	`X`	`SPA`	`@0 Metabolismo patología @5 40`
N21				`@1 138`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 09-0193729 INIST
ET :	Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes
AU :	DE GALAN (Bastiaan E.); PERKOVIC (Vlado); NINOMIYA (Toshiharu); PILLAI (Avinesh); PATEL (Anushka); CASS (Alan); NEAL (Bruce); POULTER (Neil); HARRAP (Stephen); MOGENSEN (Carl-Erik); COOPER (Mark); MARRE (Michel); WILLIAMS (Bryan); HAMET (Pavel); MANCIA (Giuseppe); WOODWARD (Mark); GLASZIOU (Paul); GROBBEE (Diederick E.); MACMAHON (Stephen); CHALMERS (John)
AF :	George Institute For International Health, University of Sydney/Sydney/Australie (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut., 16 aut., 19 aut., 20 aut.); Department of General Internal Medicine, Radboud University Nijmegen Medical Centre/Nijmegen/Pays-Bas (1 aut.); International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London/London/Royaume-Uni (8 aut.); Department of Physiology, University of Melbourne/Melbourne/Australie (9 aut.); Medical Department M, Aarhus University Hospital, Aarhus Sygehus/Aarhus/Danemark (10 aut.); Danielle Alberti Memorial Centre for Diabetes Complications, Baker Heart Research Institute/Melbourne/Australie (11 aut.); Service d'Endocrinologie Diabétologie Nutrition, Groupe Hospitalier Bichat-Claude Bernard/Paris/France (12 aut.); Department of Cardiovascular Sciences, University of Leicester School of Medicine/Leicester/Royaume-Uni (13 aut.); Research Centre, Centre hospitalier de l'Université de Montréal (CHUM)/Montreal, Québec/Canada (14 aut.); Department of Clinical Medicine and Prevention, University of Milano-Bicocca/Milan/Italie (15 aut.); Centre for Evidence-Based Practice, Institute of Health Sciences, Oxford University/Oxford/Royaume-Uni (17 aut.); Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht/Utrecht/Pays-Bas (18 aut.)
DT :	Publication en série; Niveau analytique
SO :	Journal of the American Society of Nephrology; ISSN 1046-6673; Coden JASNEU; Etats-Unis; Da. 2009; Vol. 20; No. 4; Pp. 883-892; Bibl. 41 ref.
LA :	Anglais
EA :	BP is an important determinant of kidney disease among patients with diabetes. The recommended thresholds to initiate treatment to lower BP are 130/80 and 125/75 mmHg for people with diabetes and nephropathy, respectively. We sought to determine the effects of lowering BP below these currently recommended thresholds on renal outcomes among 11,140 patients who had type 2 diabetes and participated in the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) study. Patients were randomly assigned to fixed combination perindopril-indapamide or placebo, regardless of their BP at entry. During a mean follow-up of 4.3 yr, active treatment reduced the risk for renal events by 21% (P < 0.0001), which was driven by reduced risks for developing microalbuminuria and macroalbuminuria (both P < 0.003). Effects of active treatment were consistent across subgroups defined by baseline systolic or diastolic BP. Lower systolic BP levels during follow-up, even to <110 mmHg, was associated with progressively lower rates of renal events. In conclusion, BP-lowering treatment with perindopril-indapamide administered routinely to individuals with type 2 diabetes provides important renoprotection, even among those with initial BP <120/70 mmHg. We could not identify a BP threshold below which renal benefit is lost.
CC :	002B14; 002B21E01A
FD :	Diabète de type 2; Pression sanguine; Pression artérielle; Rein; Néphrologie; Urologie
FG :	Hémodynamique; Appareil urinaire; Endocrinopathie; Maladie métabolique
ED :	Type 2 diabetes; Blood pressure; Arterial pressure; Kidney; Nephrology; Urology
EG :	Hemodynamics; Urinary system; Endocrinopathy; Metabolic diseases
SD :	Diabetes de tipo 2; Presión sanguínea; Presión arterial; Riñón; Nefrología; Urología
LO :	INIST-26049.354000185969410250
ID :	09-0193729

Links to Exploration step

Pascal:09-0193729

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes</title>
<author><name sortKey="De Galan, Bastiaan E" sort="De Galan, Bastiaan E" uniqKey="De Galan B" first="Bastiaan E." last="De Galan">Bastiaan E. De Galan</name>
<affiliation><inist:fA14 i1="01"><s1>George Institute For International Health, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of General Internal Medicine, Radboud University Nijmegen Medical Centre</s1>
<s2>Nijmegen</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Perkovic, Vlado" sort="Perkovic, Vlado" uniqKey="Perkovic V" first="Vlado" last="Perkovic">Vlado Perkovic</name>
<affiliation><inist:fA14 i1="01"><s1>George Institute For International Health, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ninomiya, Toshiharu" sort="Ninomiya, Toshiharu" uniqKey="Ninomiya T" first="Toshiharu" last="Ninomiya">Toshiharu Ninomiya</name>
<affiliation><inist:fA14 i1="01"><s1>George Institute For International Health, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pillai, Avinesh" sort="Pillai, Avinesh" uniqKey="Pillai A" first="Avinesh" last="Pillai">Avinesh Pillai</name>
<affiliation><inist:fA14 i1="01"><s1>George Institute For International Health, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Patel, Anushka" sort="Patel, Anushka" uniqKey="Patel A" first="Anushka" last="Patel">Anushka Patel</name>
<affiliation><inist:fA14 i1="01"><s1>George Institute For International Health, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cass, Alan" sort="Cass, Alan" uniqKey="Cass A" first="Alan" last="Cass">Alan Cass</name>
<affiliation><inist:fA14 i1="01"><s1>George Institute For International Health, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Neal, Bruce" sort="Neal, Bruce" uniqKey="Neal B" first="Bruce" last="Neal">Bruce Neal</name>
<affiliation><inist:fA14 i1="01"><s1>George Institute For International Health, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Poulter, Neil" sort="Poulter, Neil" uniqKey="Poulter N" first="Neil" last="Poulter">Neil Poulter</name>
<affiliation><inist:fA14 i1="03"><s1>International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Harrap, Stephen" sort="Harrap, Stephen" uniqKey="Harrap S" first="Stephen" last="Harrap">Stephen Harrap</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Physiology, University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mogensen, Carl Erik" sort="Mogensen, Carl Erik" uniqKey="Mogensen C" first="Carl-Erik" last="Mogensen">Carl-Erik Mogensen</name>
<affiliation><inist:fA14 i1="05"><s1>Medical Department M, Aarhus University Hospital, Aarhus Sygehus</s1>
<s2>Aarhus</s2>
<s3>DNK</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cooper, Mark" sort="Cooper, Mark" uniqKey="Cooper M" first="Mark" last="Cooper">Mark Cooper</name>
<affiliation><inist:fA14 i1="06"><s1>Danielle Alberti Memorial Centre for Diabetes Complications, Baker Heart Research Institute</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marre, Michel" sort="Marre, Michel" uniqKey="Marre M" first="Michel" last="Marre">Michel Marre</name>
<affiliation><inist:fA14 i1="07"><s1>Service d'Endocrinologie Diabétologie Nutrition, Groupe Hospitalier Bichat-Claude Bernard</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Williams, Bryan" sort="Williams, Bryan" uniqKey="Williams B" first="Bryan" last="Williams">Bryan Williams</name>
<affiliation><inist:fA14 i1="08"><s1>Department of Cardiovascular Sciences, University of Leicester School of Medicine</s1>
<s2>Leicester</s2>
<s3>GBR</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hamet, Pavel" sort="Hamet, Pavel" uniqKey="Hamet P" first="Pavel" last="Hamet">Pavel Hamet</name>
<affiliation><inist:fA14 i1="09"><s1>Research Centre, Centre hospitalier de l'Université de Montréal (CHUM)</s1>
<s2>Montreal, Québec</s2>
<s3>CAN</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mancia, Giuseppe" sort="Mancia, Giuseppe" uniqKey="Mancia G" first="Giuseppe" last="Mancia">Giuseppe Mancia</name>
<affiliation><inist:fA14 i1="10"><s1>Department of Clinical Medicine and Prevention, University of Milano-Bicocca</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Woodward, Mark" sort="Woodward, Mark" uniqKey="Woodward M" first="Mark" last="Woodward">Mark Woodward</name>
<affiliation><inist:fA14 i1="01"><s1>George Institute For International Health, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Glasziou, Paul" sort="Glasziou, Paul" uniqKey="Glasziou P" first="Paul" last="Glasziou">Paul Glasziou</name>
<affiliation><inist:fA14 i1="11"><s1>Centre for Evidence-Based Practice, Institute of Health Sciences, Oxford University</s1>
<s2>Oxford</s2>
<s3>GBR</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Grobbee, Diederick E" sort="Grobbee, Diederick E" uniqKey="Grobbee D" first="Diederick E." last="Grobbee">Diederick E. Grobbee</name>
<affiliation><inist:fA14 i1="12"><s1>Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht</s1>
<s2>Utrecht</s2>
<s3>NLD</s3>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Macmahon, Stephen" sort="Macmahon, Stephen" uniqKey="Macmahon S" first="Stephen" last="Macmahon">Stephen Macmahon</name>
<affiliation><inist:fA14 i1="01"><s1>George Institute For International Health, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chalmers, John" sort="Chalmers, John" uniqKey="Chalmers J" first="John" last="Chalmers">John Chalmers</name>
<affiliation><inist:fA14 i1="01"><s1>George Institute For International Health, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0193729</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0193729 INIST</idno>
<idno type="RBID">Pascal:09-0193729</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002E47</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes</title>
<author><name sortKey="De Galan, Bastiaan E" sort="De Galan, Bastiaan E" uniqKey="De Galan B" first="Bastiaan E." last="De Galan">Bastiaan E. De Galan</name>
<affiliation><inist:fA14 i1="01"><s1>George Institute For International Health, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of General Internal Medicine, Radboud University Nijmegen Medical Centre</s1>
<s2>Nijmegen</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Perkovic, Vlado" sort="Perkovic, Vlado" uniqKey="Perkovic V" first="Vlado" last="Perkovic">Vlado Perkovic</name>
<affiliation><inist:fA14 i1="01"><s1>George Institute For International Health, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ninomiya, Toshiharu" sort="Ninomiya, Toshiharu" uniqKey="Ninomiya T" first="Toshiharu" last="Ninomiya">Toshiharu Ninomiya</name>
<affiliation><inist:fA14 i1="01"><s1>George Institute For International Health, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pillai, Avinesh" sort="Pillai, Avinesh" uniqKey="Pillai A" first="Avinesh" last="Pillai">Avinesh Pillai</name>
<affiliation><inist:fA14 i1="01"><s1>George Institute For International Health, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Patel, Anushka" sort="Patel, Anushka" uniqKey="Patel A" first="Anushka" last="Patel">Anushka Patel</name>
<affiliation><inist:fA14 i1="01"><s1>George Institute For International Health, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cass, Alan" sort="Cass, Alan" uniqKey="Cass A" first="Alan" last="Cass">Alan Cass</name>
<affiliation><inist:fA14 i1="01"><s1>George Institute For International Health, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Neal, Bruce" sort="Neal, Bruce" uniqKey="Neal B" first="Bruce" last="Neal">Bruce Neal</name>
<affiliation><inist:fA14 i1="01"><s1>George Institute For International Health, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Poulter, Neil" sort="Poulter, Neil" uniqKey="Poulter N" first="Neil" last="Poulter">Neil Poulter</name>
<affiliation><inist:fA14 i1="03"><s1>International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Harrap, Stephen" sort="Harrap, Stephen" uniqKey="Harrap S" first="Stephen" last="Harrap">Stephen Harrap</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Physiology, University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mogensen, Carl Erik" sort="Mogensen, Carl Erik" uniqKey="Mogensen C" first="Carl-Erik" last="Mogensen">Carl-Erik Mogensen</name>
<affiliation><inist:fA14 i1="05"><s1>Medical Department M, Aarhus University Hospital, Aarhus Sygehus</s1>
<s2>Aarhus</s2>
<s3>DNK</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cooper, Mark" sort="Cooper, Mark" uniqKey="Cooper M" first="Mark" last="Cooper">Mark Cooper</name>
<affiliation><inist:fA14 i1="06"><s1>Danielle Alberti Memorial Centre for Diabetes Complications, Baker Heart Research Institute</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marre, Michel" sort="Marre, Michel" uniqKey="Marre M" first="Michel" last="Marre">Michel Marre</name>
<affiliation><inist:fA14 i1="07"><s1>Service d'Endocrinologie Diabétologie Nutrition, Groupe Hospitalier Bichat-Claude Bernard</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Williams, Bryan" sort="Williams, Bryan" uniqKey="Williams B" first="Bryan" last="Williams">Bryan Williams</name>
<affiliation><inist:fA14 i1="08"><s1>Department of Cardiovascular Sciences, University of Leicester School of Medicine</s1>
<s2>Leicester</s2>
<s3>GBR</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hamet, Pavel" sort="Hamet, Pavel" uniqKey="Hamet P" first="Pavel" last="Hamet">Pavel Hamet</name>
<affiliation><inist:fA14 i1="09"><s1>Research Centre, Centre hospitalier de l'Université de Montréal (CHUM)</s1>
<s2>Montreal, Québec</s2>
<s3>CAN</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mancia, Giuseppe" sort="Mancia, Giuseppe" uniqKey="Mancia G" first="Giuseppe" last="Mancia">Giuseppe Mancia</name>
<affiliation><inist:fA14 i1="10"><s1>Department of Clinical Medicine and Prevention, University of Milano-Bicocca</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Woodward, Mark" sort="Woodward, Mark" uniqKey="Woodward M" first="Mark" last="Woodward">Mark Woodward</name>
<affiliation><inist:fA14 i1="01"><s1>George Institute For International Health, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Glasziou, Paul" sort="Glasziou, Paul" uniqKey="Glasziou P" first="Paul" last="Glasziou">Paul Glasziou</name>
<affiliation><inist:fA14 i1="11"><s1>Centre for Evidence-Based Practice, Institute of Health Sciences, Oxford University</s1>
<s2>Oxford</s2>
<s3>GBR</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Grobbee, Diederick E" sort="Grobbee, Diederick E" uniqKey="Grobbee D" first="Diederick E." last="Grobbee">Diederick E. Grobbee</name>
<affiliation><inist:fA14 i1="12"><s1>Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht</s1>
<s2>Utrecht</s2>
<s3>NLD</s3>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Macmahon, Stephen" sort="Macmahon, Stephen" uniqKey="Macmahon S" first="Stephen" last="Macmahon">Stephen Macmahon</name>
<affiliation><inist:fA14 i1="01"><s1>George Institute For International Health, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chalmers, John" sort="Chalmers, John" uniqKey="Chalmers J" first="John" last="Chalmers">John Chalmers</name>
<affiliation><inist:fA14 i1="01"><s1>George Institute For International Health, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of the American Society of Nephrology</title>
<title level="j" type="abbreviated">J. Am. Soc. Nephrol.</title>
<idno type="ISSN">1046-6673</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of the American Society of Nephrology</title>
<title level="j" type="abbreviated">J. Am. Soc. Nephrol.</title>
<idno type="ISSN">1046-6673</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Arterial pressure</term>
<term>Blood pressure</term>
<term>Kidney</term>
<term>Nephrology</term>
<term>Type 2 diabetes</term>
<term>Urology</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Diabète de type 2</term>
<term>Pression sanguine</term>
<term>Pression artérielle</term>
<term>Rein</term>
<term>Néphrologie</term>
<term>Urologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">BP is an important determinant of kidney disease among patients with diabetes. The recommended thresholds to initiate treatment to lower BP are 130/80 and 125/75 mmHg for people with diabetes and nephropathy, respectively. We sought to determine the effects of lowering BP below these currently recommended thresholds on renal outcomes among 11,140 patients who had type 2 diabetes and participated in the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) study. Patients were randomly assigned to fixed combination perindopril-indapamide or placebo, regardless of their BP at entry. During a mean follow-up of 4.3 yr, active treatment reduced the risk for renal events by 21% (P < 0.0001), which was driven by reduced risks for developing microalbuminuria and macroalbuminuria (both P < 0.003). Effects of active treatment were consistent across subgroups defined by baseline systolic or diastolic BP. Lower systolic BP levels during follow-up, even to <110 mmHg, was associated with progressively lower rates of renal events. In conclusion, BP-lowering treatment with perindopril-indapamide administered routinely to individuals with type 2 diabetes provides important renoprotection, even among those with initial BP <120/70 mmHg. We could not identify a BP threshold below which renal benefit is lost.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1046-6673</s0>
</fA01>
<fA02 i1="01"><s0>JASNEU</s0>
</fA02>
<fA03 i2="1"><s0>J. Am. Soc. Nephrol.</s0>
</fA03>
<fA05><s2>20</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>DE GALAN (Bastiaan E.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>PERKOVIC (Vlado)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>NINOMIYA (Toshiharu)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>PILLAI (Avinesh)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>PATEL (Anushka)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>CASS (Alan)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>NEAL (Bruce)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>POULTER (Neil)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>HARRAP (Stephen)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>MOGENSEN (Carl-Erik)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>COOPER (Mark)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>MARRE (Michel)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>WILLIAMS (Bryan)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>HAMET (Pavel)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>MANCIA (Giuseppe)</s1>
</fA11>
<fA11 i1="16" i2="1"><s1>WOODWARD (Mark)</s1>
</fA11>
<fA11 i1="17" i2="1"><s1>GLASZIOU (Paul)</s1>
</fA11>
<fA11 i1="18" i2="1"><s1>GROBBEE (Diederick E.)</s1>
</fA11>
<fA11 i1="19" i2="1"><s1>MACMAHON (Stephen)</s1>
</fA11>
<fA11 i1="20" i2="1"><s1>CHALMERS (John)</s1>
</fA11>
<fA14 i1="01"><s1>George Institute For International Health, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>16 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>20 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of General Internal Medicine, Radboud University Nijmegen Medical Centre</s1>
<s2>Nijmegen</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Physiology, University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Medical Department M, Aarhus University Hospital, Aarhus Sygehus</s1>
<s2>Aarhus</s2>
<s3>DNK</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Danielle Alberti Memorial Centre for Diabetes Complications, Baker Heart Research Institute</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Service d'Endocrinologie Diabétologie Nutrition, Groupe Hospitalier Bichat-Claude Bernard</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Department of Cardiovascular Sciences, University of Leicester School of Medicine</s1>
<s2>Leicester</s2>
<s3>GBR</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Research Centre, Centre hospitalier de l'Université de Montréal (CHUM)</s1>
<s2>Montreal, Québec</s2>
<s3>CAN</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Department of Clinical Medicine and Prevention, University of Milano-Bicocca</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>15 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Centre for Evidence-Based Practice, Institute of Health Sciences, Oxford University</s1>
<s2>Oxford</s2>
<s3>GBR</s3>
<sZ>17 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht</s1>
<s2>Utrecht</s2>
<s3>NLD</s3>
<sZ>18 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>ADVANCE Collaborative Group</s1>
<s3>INC</s3>
</fA17>
<fA20><s1>883-892</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>26049</s2>
<s5>354000185969410250</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>41 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0193729</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of the American Society of Nephrology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>BP is an important determinant of kidney disease among patients with diabetes. The recommended thresholds to initiate treatment to lower BP are 130/80 and 125/75 mmHg for people with diabetes and nephropathy, respectively. We sought to determine the effects of lowering BP below these currently recommended thresholds on renal outcomes among 11,140 patients who had type 2 diabetes and participated in the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) study. Patients were randomly assigned to fixed combination perindopril-indapamide or placebo, regardless of their BP at entry. During a mean follow-up of 4.3 yr, active treatment reduced the risk for renal events by 21% (P < 0.0001), which was driven by reduced risks for developing microalbuminuria and macroalbuminuria (both P < 0.003). Effects of active treatment were consistent across subgroups defined by baseline systolic or diastolic BP. Lower systolic BP levels during follow-up, even to <110 mmHg, was associated with progressively lower rates of renal events. In conclusion, BP-lowering treatment with perindopril-indapamide administered routinely to individuals with type 2 diabetes provides important renoprotection, even among those with initial BP <120/70 mmHg. We could not identify a BP threshold below which renal benefit is lost.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B14</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B21E01A</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Diabète de type 2</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Type 2 diabetes</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Diabetes de tipo 2</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pression sanguine</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Blood pressure</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Presión sanguínea</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pression artérielle</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Arterial pressure</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Presión arterial</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Rein</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Kidney</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Riñón</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Néphrologie</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Nephrology</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Nefrología</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Urologie</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Urology</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Urología</s0>
<s5>08</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Hémodynamique</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Hemodynamics</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hemodinámica</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Appareil urinaire</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Urinary system</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Aparato urinario</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Endocrinopathie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Endocrinopathy</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Endocrinopatía</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie métabolique</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Metabolic diseases</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Metabolismo patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>138</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 09-0193729 INIST</NO>
<ET>Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes</ET>
<AU>DE GALAN (Bastiaan E.); PERKOVIC (Vlado); NINOMIYA (Toshiharu); PILLAI (Avinesh); PATEL (Anushka); CASS (Alan); NEAL (Bruce); POULTER (Neil); HARRAP (Stephen); MOGENSEN (Carl-Erik); COOPER (Mark); MARRE (Michel); WILLIAMS (Bryan); HAMET (Pavel); MANCIA (Giuseppe); WOODWARD (Mark); GLASZIOU (Paul); GROBBEE (Diederick E.); MACMAHON (Stephen); CHALMERS (John)</AU>
<AF>George Institute For International Health, University of Sydney/Sydney/Australie (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut., 16 aut., 19 aut., 20 aut.); Department of General Internal Medicine, Radboud University Nijmegen Medical Centre/Nijmegen/Pays-Bas (1 aut.); International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London/London/Royaume-Uni (8 aut.); Department of Physiology, University of Melbourne/Melbourne/Australie (9 aut.); Medical Department M, Aarhus University Hospital, Aarhus Sygehus/Aarhus/Danemark (10 aut.); Danielle Alberti Memorial Centre for Diabetes Complications, Baker Heart Research Institute/Melbourne/Australie (11 aut.); Service d'Endocrinologie Diabétologie Nutrition, Groupe Hospitalier Bichat-Claude Bernard/Paris/France (12 aut.); Department of Cardiovascular Sciences, University of Leicester School of Medicine/Leicester/Royaume-Uni (13 aut.); Research Centre, Centre hospitalier de l'Université de Montréal (CHUM)/Montreal, Québec/Canada (14 aut.); Department of Clinical Medicine and Prevention, University of Milano-Bicocca/Milan/Italie (15 aut.); Centre for Evidence-Based Practice, Institute of Health Sciences, Oxford University/Oxford/Royaume-Uni (17 aut.); Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht/Utrecht/Pays-Bas (18 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of the American Society of Nephrology; ISSN 1046-6673; Coden JASNEU; Etats-Unis; Da. 2009; Vol. 20; No. 4; Pp. 883-892; Bibl. 41 ref.</SO>
<LA>Anglais</LA>
<EA>BP is an important determinant of kidney disease among patients with diabetes. The recommended thresholds to initiate treatment to lower BP are 130/80 and 125/75 mmHg for people with diabetes and nephropathy, respectively. We sought to determine the effects of lowering BP below these currently recommended thresholds on renal outcomes among 11,140 patients who had type 2 diabetes and participated in the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) study. Patients were randomly assigned to fixed combination perindopril-indapamide or placebo, regardless of their BP at entry. During a mean follow-up of 4.3 yr, active treatment reduced the risk for renal events by 21% (P < 0.0001), which was driven by reduced risks for developing microalbuminuria and macroalbuminuria (both P < 0.003). Effects of active treatment were consistent across subgroups defined by baseline systolic or diastolic BP. Lower systolic BP levels during follow-up, even to <110 mmHg, was associated with progressively lower rates of renal events. In conclusion, BP-lowering treatment with perindopril-indapamide administered routinely to individuals with type 2 diabetes provides important renoprotection, even among those with initial BP <120/70 mmHg. We could not identify a BP threshold below which renal benefit is lost.</EA>
<CC>002B14; 002B21E01A</CC>
<FD>Diabète de type 2; Pression sanguine; Pression artérielle; Rein; Néphrologie; Urologie</FD>
<FG>Hémodynamique; Appareil urinaire; Endocrinopathie; Maladie métabolique</FG>
<ED>Type 2 diabetes; Blood pressure; Arterial pressure; Kidney; Nephrology; Urology</ED>
<EG>Hemodynamics; Urinary system; Endocrinopathy; Metabolic diseases</EG>
<SD>Diabetes de tipo 2; Presión sanguínea; Presión arterial; Riñón; Nefrología; Urología</SD>
<LO>INIST-26049.354000185969410250</LO>
<ID>09-0193729</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E47 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002E47 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0193729
   |texte=   Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes

Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri